Tentt

TaiLin Pharmaceuticals Acquires 58.11% of Kangyuan

Closed
HealthcareAdd-on

Deal Overview

TaiLin Pharmaceuticals (01011) has completed its acquisition of 58.11% equity in Zhejiang Kangyuan Medical Devices. The deal consideration is approximately 116 million yuan.

To complete payment, TaiLin issued and allotted 275 million new shares at an issue price of 0.45 Hong Kong dollars per share to eight sellers on March 25, 2026. The company also reported that conditions precedent in the circular were fulfilled, and that the target companies’ entire issued share capital was transferred and registered as indirect wholly-owned subsidiaries.

The transaction involves Junbinxiongdi Limited, Yue Hua Limited, and Zhong He Qun Lian Limited as target companies.

Key Details

Transaction
TaiLin Pharmaceuticals acquires Zhejiang Kangyuan Medical Devices
Deal Size
Under $10M
Reported Value
approximately 116 million yuan

Filed under

Source

Read full article on news.google.com

via GN - completed acquisition of · March 25, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →